Next PhysChem Forum: Johnson & Johnson (Belgium)
PCF2026 – Registration is now open. Secure your place today!!
Another exciting PhysChem forum edition will be hosted by Johnson & Johnson in Antwerp and Beerse
(Belgium)
on October 13-14, 2026.
Registration will open at 14.00 CET on October 13 at the Radison Blu Antwerp City Centre, followed by the afternoon scientific session and the gala dinner. The next morning on October 14, a shuttle bus will depart from the hotel and take participants to the Johnson & Johnson main campus in Beerse for the second day of the PhysChem Forum 2026.
This year’s theme is Delivery by Design: PhysChem Innovation and Predictive Analytics for New
Modalities.
Registration and full details of the event can be found below.
Accomodation
Delegates are responsible for arranging their own accommodation. We have negociated preferential room rates for those wishing to book accommodation at the designated conference hotel, the Radisson Blu Antwerp City Centre. Press here to get more info about how to reach the hotel.
Rooms are available at a discounted rate using the promotion code PHYSCHEM. Please note that this discount code applies only to the Premium room category, which is offered at a reduced rate of €183 per night (including taxes) and is fully refundable. The discounted rate applies to single occupancy in a double room. If you wish to share the room with a guest, please contact the hotel directly. The discount is also valid for additional nights before or after the conference, should you wish to arrive early or extend your stay. Please note that the promotion code is valid until Sunday, 13th September. After this date, the discounted rate will no longer be available.
A standard room with breakfast can also be booked at a lower rate directly via the hotel website; however, this option is non-refundable and is not covered by the promotion code.
Registration
Registration is now open. Please use this link.
Programme
Tuesday 13th October, Radisson Blu Hotel (Google map link).
Tuesday 13th October, Radisson Blu Hotel (Google map link).
| Session 1 - Chair: Stephane Rodde (Novartis, Switzerland) | |
| Time | Session |
| 14:00-15:30 | Registration |
| 15:30-15:40 | Welcome and introduction to PCF2026 |
| 15:40-16:20 | Learning the hard way: DMPK for bifunctional molecules Andy Pike (AstraZeneca, United Kingdom) |
| 16:20-17:00 | Designing PROTACs for Intracellular Exposure: the Role of Permeability and Physicochemical Properties Emma Inganäs (University of Gothenburg, Sweden) |
| 17:00-17:30 | Tea/coffe break |
| 17:30-18:30 | Keynote – TBD TBD |
| 18:30-19:30 | Social break |
| 19:30-22:00 | Symposium dinner |
Wednesday 14th October, J&J Beerse, Turnhoutseweg 30, 2340 Beerse (Google map link).
| Session 1- Magdalena Kierkowicz (UCB, United Kingdom) | |
| Time | Session |
| 08:30-09:00 | Late registration and poster set-up |
| 09:00-09:10 | J&J Site Welcome |
| 09:10-09:20 | Welcome from the PhysChem Forum Committee |
| 09:20-10:00 | Protacs - findings from rat intestinal perfusion and pharmacokinetic studies, demonstrating the permeability advantage achieved through the formation of amorphous nanoparticles for two PROTAC drugs Janis Niessen (Uppsala University, Sweden) |
| 10:00-10:40 | Vehicles for PROTACs in preclinical in vivo studies - not a simple task Meike Harms (Merck, XX) |
| 10:40-11:10 | Tea/coffee break and poster viewing |
| Session 2- Sigrid Stokbroekx (J&J, Belgium) | |
| Time | Session |
| 11:10-11:50 | Fast AI supported prediction of pKa values for both small and big molecules such as PROTACs Susanne Winiwarter (AstraZeneca, Sweden) |
| 11:50-12:10 | Flash poster presentations (2 mins each) |
| 12:10-13:40 | Lunch and poster viewing |
| Session 3 - Chair: Sonia Espinosa (Almirall, Spain) | |
| Time | Session |
| 13:40-14:20 | TBD TBD |
| 14:20-15:00 | Adapting foundation models to physchem applications and to newer modalities - opportunities and challenges Hugo Ceulemans (J&J, Belgium) |
| 15:00-15:40 | Poster prize award followed by tea/coffee break and poster viewing / Group picture (photo session) |
| Session 4 - Chair: Björn Wagner (Roche, Switzerland) | |
| Time | Session |
| 15:40-16:20 | Biopharmaceutical Characterisation of New Modalities Zahari Vinarov (University of Sofia, Bulgaria) |
| 16:20-17:00 | Unlocking the secrets of peptide oral absorption and success stories Katie Amssoms (J&J, Belgium) |
| 17:00-17:10 | Wrap-up and depart |
Posters
The poster session is limited to 30 posters, please indicate if you are interested in bringing one when registering. Maximum dimensions A0, or 118 x 84 cm. Deadline for registering posters is 29th September. Portrait is preferred but landscape can be accommodated.
Travel
Antwerp can be easily reached by plane. To get to the city center, the taxi ride takes about 15-20 minutes and costs around 20-30€. Alternatively, you can take bus number 51, 52, or 53 from the stop “Deurne Luchthaven” located just outside the terminal to Antwerp Central Station (travel time: 15–20 minutes, cost 2.50€).
The figure shows instructions to reach the conference hotel, the Radisson Blue Hotel in Antwerp:
Transport between Antwerp and the Johnson & Johnson Beerse site (14th October): please indicate in the registration form whether you will travel using your own transport or the J&J-arranged bus transfer. This information is required so we can arrange the correct number of buses.
Supporters and sponsors
The PhysChem Forum is very grateful to our host Johnson & Johnson and our sponsors for helping us run PCF2026 as a free-to-attend event.

ACD/Labs is a leading provider of scientific software solutions that facilitate effective decision making and digital transformation in chemical and pharmaceutical R&D. We enable organizations to leverage harmonized analytical, structural, and molecular information—for use by chemists and data scientists alike—in a FAIR-compliant environment. Our science-centric solutions, supported by cloud-enabled technologies, automate, manage, and proliferate chemically intelligent knowledge. For decades, ACD/Labs has helped leading R&D organizations through digitalization and engineering of data for AI initiatives. As part of Revvity Signals we will continue to help create efficiencies in workflows that improve productivity and accelerate scientific innovation.
Pion supports the development of lifesaving and life-enhancing drugs by providing tools for drug developers, formulations scientists, and pharmaceutical production. For early-stage drug developers, our cutting-edge analytical technologies and services enable in vitro measurements of solubility, permeability, pKa and lipophilicity, providing essential data to improve candidate selection and formulations decisions for both oral and subcutaneous dosage forms. Later in development, high-pressure homogenizers enable particle size reduction and ensure material consistency from bench- to production-scale.

Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology. Our mission is to facilitate the efficient development of optimal medicinal products, ranging from conventional to complex formulations, by leveraging scientific excellence. We are experts in all facets of dose selection and justification, including Drug Metabolism and Pharmacokinetics (DMPK), Clinical Pharmacology, Pharmaceutical Development, IND-NDA technical authoring, and GMP manufacturing. Our comprehensive suite of services encompasses consultancy, laboratory analysis, pharmacokinetic modelling and GMP manufacturing. This expertise enables us to guide clients through the entire drug development process, from initial discovery and preclinical studies to clinical trials and regulatory approval. Our focus is on designing and developing products that exhibit superior in vivo performance, robust manufacturability, and strong commercial potential. Based in Greater Manchester, UK, our cutting-edge facilities are equipped to support the rapid design, development, evaluation, and production of innovative formulations. By enhancing the value proposition of our global clients, we contribute to the advancement of new therapies, ultimately benefiting patients worldwide.

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies. Selvita was established in 2007 and currently employs almost 900 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Wroclaw, Poland, as well as Zagreb, Croatia. Selvita’s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs.

With more than 30 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology/toxicology (QSP/QST), and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide.
We offer #1-ranked, easy-to-use software (GastroPlus®, ADMET Predictor®, DILIsym®, NAFLDsym®, MonolixSuite®, and more) to bridge data mining and compound library screening with QSAR models, PK/PD model development, and PBPK/TK modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. Our clinical simulations and medical communications software platforms (Pro-ficiency Performance Management and Panorama) support our clients' study quality and communications through drug development, regulatory submission, approval, and commercialization.

The Solubility Company is a specialized technology company operating at the Discovery-Development interface, helping drug developers outline an optimized path from medicinal chemistry to the clinic. Our SPA® (Single Particle Analysis) platform allows for accurate measurement of solubility, dissolution, and various physicochemical properties (e.g., log P, pKa) using microscopic sample quantities to collect comprehensive characterization and formulation support data at the earliest stage. Removing the sample burden enables accelerated and derisked pipelines rooted in high quality experimental data. Our proprietary machine vision technology brings the advantage of microscopic sample consumption combined with speed and accuracy to the benefit of pharmaceutical research and development efforts. The Solubility Company’s service laboratories serve drug developers globally.
Our service laboratories are based in Helsinki, Finland and in Quakertown, Pennsylvania. The labs are operated by a highly skilled team with more than 50 years of experience in pharmaceutical research and development.
About the PhysChem Forum
We organise regular free-to-attend
meetings with a focus on PhysChem in drug development. Our goal is to generate
an environment for informed debate and discussion in a non-commercial setting
with excellent networking opportunities. We are supported by many
"BigPharma" and smaller pharmaceutical development companies through
the input of the PhysChem organising committee. To join our exciting
meetings please sign up to our e-mail list by dropping an e-mail to "mailshot@physchem.org.uk".
